Your session is about to expire
← Back to Search
Tipifarnib + Alpelisib for Head and Neck Cancer
Study Summary
This trial is testing a new cancer treatment for people with head and neck squamous cell carcinoma.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have completed at least one treatment cycle with specific cancer growth inhibitors.I have a GI condition that could affect how my body absorbs medication.My previous cancer treatment did not work as expected.My cancer originates from the salivary gland, thyroid, or skin.I had major surgery less than 2 weeks ago and haven't fully recovered.My tumor is driven by HRAS or PIK3CA mutations.I am currently on cancer treatment medication.I don't have severe or worsening nerve problems.I am 18 years old or older.I haven't had treatment for heart attack or stroke in the last 6 months.I have been diagnosed with lung inflammation or disease.I have been diagnosed with Type 1 diabetes or my Type 2 diabetes is not well-controlled.My head or neck cancer can't be cured with surgery or radiation.My liver, kidneys, hormone levels, and blood counts are all within normal ranges.I do not have any ongoing serious infections needing treatment.I am fully active or can carry out light work.I can swallow pills or a liquid form of medication without using a feeding tube.
- Group 1: PIK3CA-dependent (Cohort 1)
- Group 2: HRAS-dependent (Cohort 2)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are we still enrolling subjects for this research project?
"From what is published on clinicaltrials.gov, it appears as though this clinical trial is still searching for participants. The study was originally put up on December 7th, 2021 and has had its most recent update on August 29th, 2022."
Are there any participating hospitals in North America?
"The University of Wisconsin Carbone Cancer Center, Washington University, School of Medicine and Lake Nona DDU (Florida Cancer Specialists) are a few of the locations where this clinical trial is taking place. In total, there are 11 sites running this study."
What other research has been done on Tipifarnib's effectiveness?
"Currently, there are a total of 39 ongoing clinical trials studying Tipifarnib. Out of those active investigations, 7 have reached Phase 3. The majority of research teams for Tipifarnib are based in Stanford, but the 1796 locations conducting these studies are spread across the world."
Share this study with friends
Copy Link
Messenger